Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: Modeling the downstream effects

Breast Cancer Research and Treatment

Volumn 114, Issue 3, 2009, Pages 579-587

  Au, Heather Jane ^a   Golmohammadi, Kamran ^b   Younis, Tallal ^c   Verma, Shailendra ^d   Chia, Stephen ^e   Fassbender, Konrad ^b   Jacobs, Philip ^b  

^a CROSS CANCER INSTITUTE   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e Vancouver Cancer Centre   (Canada)

Author keywords

Adjuvant treatment; Breast cancer; Chemotherapy; Cost effectiveness; Taxanes

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; NAVELBINE; OXALIPLATIN; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH STATUS; LYMPH NODE METASTASIS; METASTASIS; ONCOGENE NEU; PRIORITY JOURNAL; PROBABILITY; STATISTICAL MODEL; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; MARKOV CHAINS; MEDICAL ONCOLOGY; MONTE CARLO METHOD; QUALITY-ADJUSTED LIFE YEARS; RECURRENCE; TAXOIDS; TREATMENT OUTCOME;

EID: 61449173979     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0034-1     Document Type: Article

References (41)

1. Canadian Cancer Society/National Cancer Institute of Canada (2006) Canadian cancer statistics 2006, Toronto, Canada
2. Harris JR, Lippman ME, Morrow M et al (1996) Prognostic and predictive factors in diseases of the breast. Lippincott-Raven Publishers, Philadelphia, pp 461-485
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials Lancet 365 1687 1717
4. Adjuvant Therapy for Breast Cancer (2000) NIH consensus statement online. November 1-3; cited 2006, June 21, 17(4):1-23
5. J O'Shaughnessy 2005 Extending survival with chemotherapy in metastatic breast cancer Oncologist 10 suppl 3 20 29
6. M Martin T Pienkowski J Mackey 2005 Adjuvant docetaxel for node-positive breast cancer N Engl J Med 352 2302 2313
7. JL Blum V Dieras P Mucci Lo Russo 2001 Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients Cancer 92 1759 1768
8. I Zelek S Barthier M Riofrio 2001 Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma Cancer 92 2267 2272
9. Jones S, Erban J, OVermoyer B et al (2003) Randomized trial comparing docetaxel and paclitaxel in patients with metastatic breast cancer. Presented at the 26th annual San Antonio breast cancer symposium
10. P Papaldo A Fabi C Nardoni 2003 Trastuzumab improves the prognosis in HER2-positive when compared with HER2-negative patients. Trastuzumab plus vinorelbine in HER2-positive versus vinorelbine alone in HER2-negative metastatic breast cancer patients Breast Cancer Res Treat 82 suppl 1 S9
11. DJ Slamon B Leyland-Jones S Shak 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792
12. Martin M, Pienkowski T, Mackey J et al (2003) TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients. BCIRG 001: 55 months followup. Presented at the 26th annual San Antonio breast cancer symposium
13. Alberta Vital Statistics 2000-2003
14. J Bedwinek 1994 Natural history and management of isolated local-regional recurrence following mastectomy Semin Radiat Oncol 4 260 269
15. M Clemons S Danson T Hamilton 2001 Locoregionally recurrent breast cancer: incidence, risk factors and survival Cancer Treat Rev 27 67 82
16. CC Zielilnski 2003 Treatment choices for second-line chemotherapy of metastatic breast cancer Breast Cancer Res Treat 81 suppl 1 S33 S36
17. FA Sonnenberg JR Beck 1993 Markov models in medical decision making: a practical guide Med Decis Making 13 322 338
18. J Crown V Dieras M Kaufmann 2002 Chemotherapy for metastatic breast cancer-report of a European expert panel Lancet Oncol 3 719 727
19. K Fassbender R Fainsinger C Brenneis 2005 Utilization and costs of the introduction of system-wide palliative care in Alberta, 1993-2000 Palliat Med 19 513 520
20. RE Brown J Hutton A Burrell 2001 Cost effectiveness of treatment options in advanced breast cancer in the UK Pharmacoeconomics 19 1091 1102
21. JA Hayman BE Hillner JR Harris 2000 Cost-effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer J Clin Oncol 16 1022 1029
22. PP Leung IF Tannock AM Oza 1999 Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer J Clin Oncol 17 3082 3090
23. RE Brown J Hutton 1998 Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients Anticancer Drugs 9 899 907
24. SC Martin DD Gagnon L Zhang 2003 Cost-utility analysis of survival with epoetin-alpha versus placebo in stage IV breast cancer Pharmacoeconomics 21 1153 1169
25. Drummond MF, Scupher MJ, Torrance GW et al (2005) Methods for the economic evaluation of health care programmes, 3rd edn. Oxford University press, Oxford
26. Case Mix number 297, Alberta Health and Wellness, costs in Alberta, 2002
27. SF Hurley RM Huggins RD Snyder 1992 The cost of breast cancer recurrences Br J Cancer 65 449 455
28. Martin M, Lluch A, Segui MA (2004) Prophylactic growth factor (GF) support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-negative breast cancer (BC): an interim safety analysis of the GEICAM 9805 study. J Clin Oncol; 22(suppl 14):620. Proc ASCO (Post-Meeting Edition)
29. MJ Piccart-Gebhart M Procter B Leyland-Jones 2005 Trustuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659 1672
30. EH Romond EA Perez J Bryant 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673 1684
31. TreeAge software Inc. (2005) Williamstown, MA
32. RA Hirth ME Chernew E Miller 2000 Willingness to pay for a quality-adjusted life year: in search of a standard Health Econ 20 332 342
33. Greene FL, Page DL, Fleming ID et al (2002) AJCC cancer staging handbook, 6th edn. Springer, New York
34. TJ Smith J Khatcheressian GH Lyman 2006 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based, clinical practice guidelines J Clin Oncol 24 3187 3205
35. BE Hillner JC Weeks CE Desch 2000 Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis J Clin Oncol 18 72 79
36. M Neyt J Albrecht V Cocquyt 2006 An economic evaluation of Herceptin in adjuvant setting: the Breast Cancer International Research Group 006 trial Ann Oncol 17 381 390
37. EB Elkin MC Weinstein EP Winer 2004 HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis J Clin Oncol 22 854 863
38. BE Hillner D Schrag DJ Sargent 2005 Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma Cancer 104 1871 1084
39. RP Rocconi AS Case JM Straughn 2006 Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: a cost-effectiveness analysis Cancer 107 536 543
40. PA Ubel RA Hirth ME Chernew 2003 What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 163 1637 1641
41. DF Hayes AD Thor LG Dressler 2007 HER2 and response to paclitaxel in node-positive breast cancer N Engl J Med 357 1496 1506